Utebzi Approved in the U.S. for Adults With Complicated Urinary Tract Infections
June 18, 2026
June 18, 2026
LONDON, England, June 18 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on June 17, 2026:
* * *
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
* First and only oral carbapenem antibiotic approved in the US
* Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment/1
* More than 3 m . . .
* * *
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
* First and only oral carbapenem antibiotic approved in the US
* Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment/1
* More than 3 m . . .